Literature DB >> 24227768

A double blind, within subject comparison of spontaneous opioid withdrawal from buprenorphine versus morphine.

D Andrew Tompkins1, Michael T Smith, Miriam Z Mintzer, Claudia M Campbell, Eric C Strain.   

Abstract

Preliminary evidence suggests that there is minimal withdrawal after the cessation of chronically administered buprenorphine and that opioid withdrawal symptoms are delayed compared with those of other opioids. The present study compared the time course and magnitude of buprenorphine withdrawal with a prototypical μ-opioid agonist, morphine. Healthy, out-of-treatment opioid-dependent residential volunteers (N = 7) were stabilized on either buprenorphine (32 mg/day i.m.) or morphine (120 mg/day i.m.) administered in four divided doses for 9 days. They then underwent an 18-day period of spontaneous withdrawal, during which four double-blind i.m. placebo injections were administered daily. Stabilization and spontaneous withdrawal were assessed for the second opioid using the same time course. Opioid withdrawal measures were collected eight times daily. Morphine withdrawal symptoms were significantly (P < 0.05) greater than those of buprenorphine withdrawal as measured by mean peak ratings of Clinical Opiate Withdrawal Scale (COWS), Subjective Opiate Withdrawal Scale (SOWS), all subscales of the Profile of Mood States (POMS), sick and pain (0-100) Visual Analog Scales, systolic and diastolic blood pressure, heart rate, respiratory rate, and pupil dilation. Peak ratings on COWS and SOWS occurred on day 2 of morphine withdrawal and were significantly greater than on day 2 of buprenorphine withdrawal. Subjective reports of morphine withdrawal resolved on average by day 7. There was minimal evidence of buprenorphine withdrawal on any measure. In conclusion, spontaneous withdrawal from high-dose buprenorphine appears subjectively and objectively milder compared with that of morphine for at least 18 days after drug cessation.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24227768      PMCID: PMC3912547          DOI: 10.1124/jpet.113.209478

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  52 in total

1.  Validation of the Insomnia Severity Index as an outcome measure for insomnia research.

Authors:  C H. Bastien; A Vallières; C M. Morin
Journal:  Sleep Med       Date:  2001-07       Impact factor: 3.492

Review 2.  Current pharmacotherapies for opioid dependence.

Authors:  T R Kosten
Journal:  Psychopharmacol Bull       Date:  1990

3.  The effects of morphine- and nalorphine- like drugs in the nondependent and morphine-dependent chronic spinal dog.

Authors:  W R Martin; C G Eades; J A Thompson; R E Huppler; P E Gilbert
Journal:  J Pharmacol Exp Ther       Date:  1976-06       Impact factor: 4.030

4.  Human pharmacology and abuse potential of the analgesic buprenorphine: a potential agent for treating narcotic addiction.

Authors:  D R Jasinski; J S Pevnick; J D Griffith
Journal:  Arch Gen Psychiatry       Date:  1978-04

5.  Delta opioid antagonist effects of buprenorphine in rhesus monkeys.

Authors:  S S Negus; J M Bidlack; N K Mello; M S Furness; K C Rice; M R Brandt
Journal:  Behav Pharmacol       Date:  2002-11       Impact factor: 2.293

6.  Relative bioavailability of different buprenorphine formulations under chronic dosing conditions.

Authors:  Eric C Strain; David E Moody; Kenneth B Stoller; Sharon L Walsh; George E Bigelow
Journal:  Drug Alcohol Depend       Date:  2004-04-09       Impact factor: 4.492

7.  Concurrent validation of the Clinical Opiate Withdrawal Scale (COWS) and single-item indices against the Clinical Institute Narcotic Assessment (CINA) opioid withdrawal instrument.

Authors:  D Andrew Tompkins; George E Bigelow; Joseph A Harrison; Rolley E Johnson; Paul J Fudala; Eric C Strain
Journal:  Drug Alcohol Depend       Date:  2009-08-03       Impact factor: 4.492

8.  In vivo receptor binding of the opiate partial agonist, buprenorphine, correlated with its agonistic and antagonistic actions.

Authors:  J E Dum; A Herz
Journal:  Br J Pharmacol       Date:  1981-11       Impact factor: 8.739

9.  Buprenorphrine: demonstration of physical dependence liability.

Authors:  J Dum; J Bläsig; A Herz
Journal:  Eur J Pharmacol       Date:  1981-03-26       Impact factor: 4.432

10.  Effects of buprenorphine maintenance dose on mu-opioid receptor availability, plasma concentrations, and antagonist blockade in heroin-dependent volunteers.

Authors:  Mark K Greenwald; Chris-Ellyn Johanson; David E Moody; James H Woods; Michael R Kilbourn; Robert A Koeppe; Charles R Schuster; Jon-Kar Zubieta
Journal:  Neuropsychopharmacology       Date:  2003-11       Impact factor: 7.853

View more
  13 in total

1.  Opiate withdrawal syndrome in buprenorphine abusers admitted to a rehabilitation center in Tunisia.

Authors:  Ines Derbel; Asma Ghorbel; Férièle Messadi Akrout; Abdelmajid Zahaf
Journal:  Afr Health Sci       Date:  2016-12       Impact factor: 0.927

2.  Effect of lofexidine on cardiac repolarization during treatment of opioid withdrawal.

Authors:  Börje Darpö; Mark Pirner; James Longstreth; Georg Ferber
Journal:  Drug Alcohol Depend       Date:  2019-09-27       Impact factor: 4.492

Review 3.  Buprenorphine for managing opioid withdrawal.

Authors:  Linda Gowing; Robert Ali; Jason M White; Dalitso Mbewe
Journal:  Cochrane Database Syst Rev       Date:  2017-02-21

4.  IL-4 mediated by HSV vector suppresses morphine withdrawal response and decreases TNFα, NR2B, and pC/EBPβ in the periaqueductal gray in rats.

Authors:  H Yi; T Iida; S Liu; D Ikegami; Q Liu; A Iida; D A Lubarsky; S Hao
Journal:  Gene Ther       Date:  2017-03-16       Impact factor: 5.250

Review 5.  Discontinuation of buprenorphine maintenance therapy: perspectives and outcomes.

Authors:  Brandon S Bentzley; Kelly S Barth; Sudie E Back; Sarah W Book
Journal:  J Subst Abuse Treat       Date:  2014-12-30

6.  Evidence for spontaneous cannabinoid withdrawal in mice.

Authors:  Carol Paronis; Christos Iliopoulos-Tsoutsouvas; Ioannis Papanastasiou; Alex Makriyannis; Jack Bergman; Spyros P Nikas
Journal:  Behav Pharmacol       Date:  2022-04-01       Impact factor: 2.293

Review 7.  The Cholinergic System as a Treatment Target for Opioid Use Disorder.

Authors:  Kevin P Jensen; Elise E DeVito; Sarah Yip; Kathleen M Carroll; Mehmet Sofuoglu
Journal:  CNS Drugs       Date:  2018-11       Impact factor: 5.749

8.  Buprenorphine for Chronic Pain: a Systemic Review.

Authors:  Michael A Fishman; Phillip S Kim
Journal:  Curr Pain Headache Rep       Date:  2018-10-05

9.  A Novel Maintenance Therapeutic for Opioid Use Disorder.

Authors:  Beth Youngblood; Kevin Li; Donald R Gehlert; Julio C Medina; Neil Schwartz
Journal:  J Pharmacol Exp Ther       Date:  2021-05-19       Impact factor: 4.402

10.  Effect of Moderate Exercise on Serum Interferon-Gamma and Interleukin-17 Levels in the Morphine Withdrawal Period.

Authors:  Ali Heidarianpour; Majid Vahidian Rezazadeh; Alireza Zamani
Journal:  Int J High Risk Behav Addict       Date:  2016-02-13
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.